Luke Timmerman
Journalist, Founder and Editor at Timmerman Report
Biotech journalist. Founder @TimmermanReport.
Articles
-
3 weeks ago |
timmermanreport.com | Luke Timmerman
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
-
3 weeks ago |
timmermanreport.com | Luke Timmerman
Timmerman Traverse is looking for a few good men and women. Opportunities are here for people who are physically fit, enjoy nature, thrive in community, and who want to roll up the sleeves for worthy causes — including cancer research, sickle cell disease and fighting poverty. Here’s how to get involved. Timmerman Traverse for Life Science CaresThis 2-day expedition will be in the North Cascades of Washington state Aug. 17-20, 2025.
-
3 weeks ago |
timmermanreport.com | David Shaywitz |Luke Timmerman
This week featured a rare crossing of the streams, as the buttoned-down world of cancer research met the buzzy world of exercise and wellness. One result: a randomized controlled study of exercise in 889 cancer patients published in the New England Journal of Medicine (NEJM), and accompanied by a torrent of enthusiastic coverage in the popular press. Another: the publication of two important and thoughtful commentaries about this study, analyses that are the focus of today’s column.
-
4 weeks ago |
timmermanreport.com | Luke Timmerman
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
-
1 month ago |
timmermanreport.com | Luke Timmerman
Ethan Weiss and Josh Lehrer are today’s guests on The Long Run. Ethan is the co-founder and chief scientific officer of South San Francisco-based Marea Biosciences. Josh is the CEO. They are seeking to blaze a new trail with a drug to reduce the risk of cardiovascular disease and type 2 diabetes. It’s a monoclonal antibody aimed at ANGPTL4. There are people with a mutation of the gene who have considerably lower levels of triglycerides and remnant cholesterol.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 34K
- Tweets
- 17K
- DMs Open
- No
Request an Invitation to the Timmerman Traverse. https://t.co/kwaTGUFrLU
Exercise vs. Cancer. How to think about the latest study.
My new @timmermanreport column discusses recent @NEJM study linking exercise & cancer recovery, focusing on the methodological questions raised by @drjohnm & the patient-focused concerns raised by @GoldsackJen https://t.co/cI2HEDSNht @ldtimmerman @zakkohane @goldbergcarey
A New (and Old) Idea for Cardiovascular Disease & Diabetes. @ethanjweiss & Josh Lehrer @Marea_tx are the latest guests on The Long Run. https://t.co/buhUZV1X6d
